21101-79-1

Basic information

• Product Name: 2-(ETHYLTHIO)BENZOIC ACID
• Synonyms: 2-(ethylthio)benzoic acid(SALTDATA: FREE)
• CAS NO: 21101-79-1
• Molecular Formula: C₉H₁₀O₂S
• Molecular Weight: 182.24
• Mol File: 21101-79-1.mol
• Article Data: 17

Chemical Properties

• Melting Point: 130-131 °C
• Boiling Point: 310.1°Cat760mmHg
• Flash Point: 141.4°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 0.000263mmHg at 25°C
• Refractive Index: 1.596
• PKA: 3.52±0.36(Predicted)
• CAS DataBase Reference: 2-(ETHYLTHIO)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(ETHYLTHIO)BENZOIC ACID(21101-79-1)
• EPA Substance Registry System: 2-(ETHYLTHIO)BENZOIC ACID(21101-79-1)

Safety Data

• Hazardous Substances Data: 21101-79-1(Hazardous Substances Data)

Usage

General Description

2-(ethylthio)benzoic acid, also known as 2-ethylthiobenzoic acid, is an organic compound with the chemical formula C9H10O2S. It is a derivative of benzoic acid, with the addition of an ethylthio group (-C2H5S) in the ortho position. 2-(ETHYLTHIO)BENZOIC ACID is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various pharmaceuticals and agrochemicals. It has also been studied for its potential anti-inflammatory and analgesic properties. The ethylthio group adds some bulk and steric hindrance, which may impact the compound's reactivity and biological activity.

InChI:InChI=1/C9H10O2S/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3,(H,10,11)

Upstream product

• 3795-78-6 2-ethylsulfanyl-benzoic acid methyl ester 
• 4892-02-8 Methyl thiosalicylate 
• 147-93-3 Thiosalicylic acid 
• 100-68-5 methyl-phenyl-thioether 
• 546-74-7 sodium ethyl sulfate 
• 64-67-5 diethyl sulfate 
• 140-89-6 potassium ethyl xanthogenate 
• 118-92-3 anthranilic acid 
• 109-72-8 n-butyllithium 
• 60-29-7 diethyl ether 
• 622-38-8 Ethyl phenyl sulfide 
• 74-96-4 ethyl bromide 
• 75-03-6 ethyl iodide 
• 16671-86-6 2-thiocyanatobenzoic acid 

Downstream Products

• 100058-70-6 Ethyl 2-(ethylthio)benzoate 
• 173312-15-7 2-ethylsulfanyl benzoic acid chloride 
• 54705-17-8 o-ethylmercapto-benzamine 
• 492-22-8 thio-xanthene-9-one 
• 1527-13-5 2-Phenylthiobenzoesaeureethylester 
• 37527-69-8 (2-ethylsulfanyl-phenyl)-methanol 
• 1383944-92-0 2-(2-ethyl-sulfanyl-phenyl)-5-trifluoromethyl-benzoxazole 
• 1383944-56-6 6-bromo-2-(2-ethyl-sulfanyl-phenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 
• 1383947-66-7 2-(2-ethylsulfanyl-phenyl)-5-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-1H-benzimidazole 
• 1383947-17-8 2-(2-ethylsulfanyl-phenyl)-1-methyl-5-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-1H-benzimidazole 
• 1383947-16-7 2-(2-ethylsulfanyl-phenyl)-1-methyl-6-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-1H-benzimidazole 
• 1383945-64-9 2-(2-ethylsulfanylphenyl)-3-methyl-5-trifluoromethyl-3H-imidazo[4,5-b]pyridine 
• 1383944-35-1 3-ethyl-2-(2-ethylsulfanylphenyl)-6-trifluoromethyl-3H-imidazo[4,5-b]pyridine 
• 1383945-38-7 6-amino-2-(2-ethylsulfanylphenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 

Relevant articles and documents

-

-

DNA binding and antitumor activities of platinum(IV) and zinc(II) complexes with some S-alkyl derivatives of thiosalicylic acid

A series of complexes of platinum(IV) (C1–C5) and zinc(II) (C6–C10) with S-alkyl derivatives of thiosalicylic acid were prepared and characterized. The interactions of the complexes with calf thymus DNA were analyzed by absorption (UV–Vis) and emission spectral studies (ethidium bromide displacement studies). The cytotoxic activities of complexes C1–C10 were determined against mouse B cell lymphocytic leukemia cells (BCL1), human B-prolymphocytic leukemia (JVM-13), mouse mammary carcinoma cells (4T1), and human mammary carcinoma cells (MDA-MB-468) and compared to the activities of the free ligand precursors and cisplatin. The cytotoxicities of the platinum(IV) and zinc(II) complexes toward mouse tumor cell lines were higher compared with their effects on human tumor cell lines. The zinc(II) complex C9 showed the highest antitumor activity toward the tested human cell lines, while the platinum(IV) complex C4 exhibited the highest antitumor activity toward mouse BCL1 and 4T1 cells. Both C4 and C9 have ligands derived from S-propyl thiosalicylic acid.

New piperazine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof

The present invention relates to a novel piperazine derivative having an anti-cancer effect, a combination therapeutic effect with radiation, and an anti-diabetic effect, and to a medical use thereof. The piperazine derivatives are PPAR-γ ligand, and have